Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Gains from Investment Securities (2018 - 2025)

BioNexus Gene Lab's Gains from Investment Securities history spans 7 years, with the latest figure at -$2155.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 83.51% year-over-year to -$2155.0; the TTM value through Sep 2025 reached $166173.0, down 64.79%, while the annual FY2024 figure was $141000.0, 72.45% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$2155.0 at BioNexus Gene Lab, up from -$7590.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $511740.0 in Q4 2023 and bottomed at -$370755.0 in Q3 2022.
  • The 5-year median for Gains from Investment Securities is -$2155.0 (2025), against an average of $67877.1.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 1603.44% in 2023 before it crashed 363025.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $83547.0 in 2021, then plummeted by 140.74% to -$34038.0 in 2022, then surged by 1603.44% to $511740.0 in 2023, then plummeted by 64.66% to $180842.0 in 2024, then tumbled by 101.19% to -$2155.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Gains from Investment Securities are -$2155.0 (Q3 2025), -$7590.0 (Q2 2025), and -$4924.0 (Q1 2025).